 |
|
| Hematology/Oncology |
|
| • |
ABL Kinase Domain Mutation in CML |
| • |
ABL T315I Mutation in CML |
| • |
Acute Leukemia Follow-up Panel |
| • |
Alpha-Fetoprotein
(AFP) |
| • |
AML1/ETO
t(8;21) Quantitative Real-Time PCR |
| • |
B-Cell
Gene Rearrangement, PCR |
| • |
B-Cell, Patient-specific Monitoring |
| • |
bcr/abl
Gene Rearrangement, Quantitative PCR |
| • |
Beta-2-Microglobulin, Serum |
| • |
Breast Cancer Gene Expression Ratio (HOXB13:IL17BR) |
| • |
CA 125 |
| • |
CA
15-3 |
| • |
CA 19-9 |
| • |
CA 27.29 |
| • |
CA
72-4 |
| • |
Campath®′ Sensitivity (CD52) |
| • |
Carcinoembryonic
Antigen (CEA) |
| • |
CBFB/MYH11
inv(16), Quantitative Real-time PCR |
| • |
CD25,
IHC with Interpretation |
| • |
CD55 and CD59 Expression,
Red Cells and Granulocytes |
| • |
CD117
(c-kit), IHC with Interpretation |
| • |
CellSearch®′
Circulating Tumor Cells |
| • |
Chromosome Analysis |
| • |
Chronic Lymphocytic Leukemia (CLL)/Lymphoma Diagnostic Panel |
| • |
Chronic Lymphocytic Leukemia (CLL)/Lymphoma Follow-up Panel |
| • |
Chronic Lymphocytic Leukemia
IgVH Mutation
Status |
| • |
c-kit Mutation Analysis, Plasma-based, Leumeta™ |
| • |
CLL Prognostic Panel |
| • |
Comprehensive Hematopathology Report |
| • |
Cytology,
Liquid-Based Pap Test |
| • |
Cytology,
Non-gynecological |
| • |
Diagnostic Consultation, Paraffin Block or Referred Slides |
| • |
Dihydropyrimidine Dehydrogenase (DPYD) Gene Mutation Analysis |
| • |
DNA Cell Cycle Analysis |
| • |
E-cadherin |
| • |
EGFR
Pathway (KRAS with Reflex to NRAS, BRAF) |
| • |
Epidermal Growth Factor
Receptor (EGFR) |
| • |
Estrogen and Progesterone Receptors |
| • |
Fecal
Globin by Immunochemistry (InSure®′) |
| • |
Fibroblast Growth Factor (FGF2) |
| • |
FIP1L1-PDGFRA Gene Rearrangement [del (4q12)], Real-time PCR |
| • |
FISH, ALCL, ALK, 2p23 Rearrangements |
| • |
FISH, ALL, +4, +10, +17 |
| • |
FISH, ALL, Extended Panel |
| • |
FISH, ALL, Pre-B Panel |
| • |
FISH, ALL,
TEL/AML1 Translocation (12;21) |
| • |
FISH, ALL/NHL, MYC-BA, 8q24 Rearrangement |
| • |
FISH, B-Cell Chronic Lymphocytic Leukemia (B-CLL) Panel |
| • |
FISH, B-Cell Malignancy, IGH, 14q32 Rearrangement |
| • |
FISH, Burkitt’s/NHL/ALL, IGH/MYC, t(8;14) |
| • |
FISH,
Chromosome 20q Deletion |
| • |
FISH,
CML/ALL, bcr/abl Translocation 9;22 |
| • |
FISH, Follicular Lymphoma, IGH/BCL2, t(14;18) |
| • |
FISH, HER-2/neu, Paraffin Block |
| • |
FISH, MALT Lymphoma, AP12/MALT1, t(11;18) |
| • |
FISH, MALT Lymphoma, MALT1, 18q21 Rearrangement |
| • |
FISH, MALT Lymphoma, MALT1, rea18q21 with Reflex to AP12/MALT1,
t(11;18) |
| • |
FISH, Mantle Cell Lymphoma, IGH/CCND1, t(11;14) |
| • |
FISH,
Myeloid Disorders Profile |
| • |
FISH,
Vysis®′ UroVysion™′, Bladder Cancer |
| • |
Follicular Lymphoma, bcl-2/JH t(14;18), Real-time PCR |
| • |
Hairy Cell Leukemia (HCL)/Lymphoma Follow-up Panel |
| • |
Hairy Cell Leukemia Panel, IHC |
| • |
HE4, Ovarian Cancer Monitoring |
| • |
Hematopathology
Morphologic Evaluation |
| • |
HER2,
ELISA |
| • |
HER2 (HercepTest®′), IHC with Reflex to
FISH |
| • |
Hodgkin Lymphoma Panel, IHC |
|
• |
HPV
Genotypes 16 and 18 |
|
• |
HPV, High Risk DNA, Hybrid Capture II |
|
• |
HTLV-I/II Antibody, EIA with Positives Reflexed to Western Blot |
| • |
Immunohistochemistry (IHC) Marker |
| • |
Interleukin-2 Receptor |
| • |
Intracellular Markers by Flow Cytometry |
| • |
JAK2 and MPL
Mutation Analysis |
| • |
Ki-67, IHC |
| • |
KRAS Mutation Analysis |
| • |
Leukemia/Lymphoma
Evaluation, Flow Cytometry |
| • |
Lipid Associated Sialic Acid
(LSA, LASA) |
| • |
Lymphoma Panel, IHC |
| • |
Mantle Cell Lymphoma, bcl-1/JH,
t(11;14), Real-time PCR |
| • |
Mantle Cell Lymphoma (Small Lymphocytic) Panel, IHC |
| • |
Micrometastasis Detection |
| • |
Microsatellite
Instability (MSI), HNPCC |
| • |
MLH1, MSH2, and MSH6 Mutations for HNPCC |
| • |
Mylotarg®′
Sensitivity (CD33) |
| • |
Neuron Specific Enolase (NSE) |
| • |
Nuclear Matrix Proteins
(NMP) |
| • |
ONTAK®′ Sensitivity (CD25) |
| • |
p53 Oncoprotein and Gene Mutation |
| • |
PML/RARA
t(15;17) Translocation, FISH and Quantitative Real-Time PCR |
| • |
Prostate Specific Antigen
(PSA), Free |
| • |
Prostate Specific Antigen (PSA), Total |
| • |
Prostate Specific Antigen (PSA), Ultrasensitive |
| • |
Rituxan®′ Sensitivity (CD20) |
| • |
TA90
(Melanoma-associated Antigen) |
| • |
T-Cell, Natural Killer Cell, and Anaplastic Large Cell Lymphoma Panel, IHC |
| • |
T-Cell
Receptor (TCR) Gene Rearrangement |
| • |
Tissue,
Gastrointestinal Pathology Report |
| • |
Tissue Pathology and Consultation |
| • |
TPMT Genotype |
| • |
UGT1A1 Gene Polymorphism (TA Repeat) |
| • |
ZAP-70 |